Browse > Article
http://dx.doi.org/10.7314/APJCP.2014.15.12.4951

Differential Expression of IQGAP1/2 in Hepatocellular Carcinoma and its Relationship with Clinical Outcomes  

Xia, Fa-Da (Department of General Surgery, Xiangya Hospital, Central South University)
Wang, Zhuo-Lu (Department of General Surgery, Xiangya Hospital, Central South University)
Chen, Hong-Xi (Department of General Surgery, Xiangya Hospital, Central South University)
Huang, Yun (Department of General Surgery, Xiangya Hospital, Central South University)
Li, Jin-Dong (Department of General Surgery, Xiangya Hospital, Central South University)
Wang, Zhi-Ming (Department of General Surgery, Xiangya Hospital, Central South University)
Li, Xin-Ying (Department of General Surgery, Xiangya Hospital, Central South University)
Publication Information
Asian Pacific Journal of Cancer Prevention / v.15, no.12, 2014 , pp. 4951-4956 More about this Journal
Abstract
Purpose: To investigate IQGAP1 and IQGAP2 expression in hepatocellular carcinoma (HCC) and itsassociation with HCC clinicopathological characteristics and survival outcomes. Methods: IQGAP1 and IQGAP2 mRNA and protein were measured in HCC tissues, para-tumor tissues and normal tissues by RT-PCR and Western blotting. We further examined 150 HCC samples with adjacent para-tumor tissues and 11 normal specimens by immunohistochemistry to evaluate the correlation of IQGAP1 and IQGAP2 with clinicopathological features and prognosis. Results: IQGAP1 mRNA and protein were up-regulated while IQGAP2 mRNA and protein were down-regulated in human HCC tissues compared with para-tumor and normal liver tissues (p<0.05). IQGAP1 expression was higher in primary HCC (122/150, 81.3%) than matched adjacent tissues (30/150, 20%, p<0.001), whereas IQGAP2 was lower (31/150, 20.7% as compared to 112/150, 74.7%, P<0.001). Positive IQGAP1 expression correlated with larger tumor size (p=0.002), advanced TNM stage (p=0.002) and tumor differentiation (III and IV, p=0.034). Negative IQGAP2 expression was significantly associated with larger tumor size (p=0.009), multicentric tumor occurrence (p=0.01), advanced TNM stage (0.009) and tumor differentiation (III and IV, p=0.020). Survival analysis revealed that patients with either IQGAP1+ or IQGAP2-tumors had significantly reduced disease-free survival (p<0.001 and 0.006 respectively) and overall survival (p<0.001 for both). Multivariate analysis showed that IQGAP1/2 switch was an independent prognosis factor for disease-free survival (HR=2.824) and overall survival (HR=2.189). Conclusion: Positive IQGAP1 and negative IQGAP2 expression were closely correlated with tumor progression and could be used as adjunctive biomarkers to improve prognostication for HCC patients.
Keywords
IQGAP1; IQGAP2; hepatocellular carcinoma; survival analysis;
Citations & Related Records
Times Cited By KSCI : 4  (Citation Analysis)
연도 인용수 순위
1 White CD, Brown MD, Sacks DB (2009). IQGAPs in cancer: a family of scaffold proteins underlying tumorigenesis. Febs Lett, 583, 1817-24.   DOI   ScienceOn
2 Walch A, Seidl S, Hermannstadter C, et al (2008). Combined analysis of Rac1, IQGAP1, Tiam1 and E-cadherin expression in gastric cancer. Mod Pathol, 21, 544-52.   DOI   ScienceOn
3 Wang JB, Sonn R, Tekletsadik YK, Samorodnitsky D, Osman MA (2009). IQGAP1 regulates cell proliferation through a novel CDC42-mTOR pathway. J Cell Sci, 122, 2024-33.   DOI   ScienceOn
4 Wang NY, Wang C, Li W, et al (2014). Prognostic value of serum AFP, AFP-L3, and GP73 in monitoring short-term treatment response and recurrence of hepatocellular carcinoma after radiofrequency ablation. Asian Pac J Cancer Prev, 15, 1539-44.   과학기술학회마을   DOI   ScienceOn
5 White CD, Erdemir HH, Sacks DB (2012). IQGAP1 and its binding proteins control diverse biological functions. Cell Signal, 24, 826-34.   DOI   ScienceOn
6 White CD, Khurana H, Gnatenko DV, et al (2010). IQGAP1 and IQGAP2 are reciprocally altered in hepatocellular carcinoma. BMC Gastroenterol, 10, 125.   DOI   ScienceOn
7 Yu XL (2014). Serum peroxiredoxin 3 is a useful biomarker for early diagnosis and assessemnt of prognosis of hepatocellular carcinoma in Chinese patients. Asian Pac J Cancer Prev, 15, 2979-86.   과학기술학회마을   DOI
8 McCallum SJ, Wu WJ, Cerione RA (1996). Identification of a putative effector for Cdc42Hs with high sequence similarity to the RasGAP-related protein IQGAP1 and a Cdc42Hs binding partner with similarity to IQGAP2. J Biol Chem, 271, 21732-7.   DOI   ScienceOn
9 Joyal JL, Annan RS, Ho YD, et al (1997). Calmodulin modulates the interaction between IQGAP1 and Cdc42. Identification of IQGAP1 by nanoelectrospray tandem mass spectrometry. J Biol Chem, 272, 15419-25.   DOI   ScienceOn
10 Luo R, Zhang M, Liu L, et al (2013). Decrease of fibulin-3 in hepatocellular carcinoma indicates poor prognosis. PLoS One, 8, e70511.   DOI
11 Maluccio M, Covey A (2012). Recent progress in understanding, diagnosing, and treating hepatocellular carcinoma. CA Cancer J Clin, 62, 394-9.   DOI
12 Nishikawa H, Kimura T, Kita R, Osaki Y (2013). Treatment for hepatocellular carcinoma in elderly patients: a literature review. J Cancer, 4, 635-43.   DOI   ScienceOn
13 Schmidt VA (2012). Watch the GAP: emerging roles for IQ motif-containing GTPase-activating proteins IQGAPs in hepatocellular carcinoma. Int J Hepatol, 2012, 958673.
14 Schmidt VA, Chiariello CS, Capilla E, Miller F, Bahou WF (2008). Development of hepatocellular carcinoma in Iqgap2-deficient mice is IQGAP1 dependent. Mol Cell Biol, 28, 1489-502.   DOI   ScienceOn
15 Thomas M (2009). Molecular targeted therapy for hepatocellular carcinoma. J Gastroenterol, 44, 136-41.   DOI
16 Van Hengel J, D'Hooge P, Hooghe B, et al (2008). Continuous cell injury promotes hepatic tumorigenesis in cdc42-deficient mouse liver. Gastroenterology, 134, 781-92.   DOI   ScienceOn
17 Gnatenko DV, Xu X, Zhu W, Schmidt VA (2013). Transcript profiling identifies iqgap2(-/-) mouse as a model for advanced human hepatocellular carcinoma. PLoS One, 8, e71826.   DOI
18 Gomaa AI, Khan SA, Toledano MB, Waked I, Taylor-Robinson SD (2008). Hepatocellular carcinoma: epidemiology, risk factors and pathogenesis. World J Gastroenterol, 14, 4300-8.   DOI   ScienceOn
19 Dong PX, Jia N, Xu ZJ, et al (2008). Silencing of IQGAP1 by shRNA inhibits the invasion of ovarian carcinoma HO-8910PM cells in vitro. J Exp Clin Cancer Res, 27, 77-84.   DOI   ScienceOn
20 Elliott SF, Allen G, Timson DJ (2012). Biochemical analysis of the interactions of IQGAP1 C-terminal domain with CDC42. World J Biol Chem, 3, 53-60.   DOI
21 Grohmanova K, Schlaepfer D, Hess D, et al (2004). Phosphorylation of IQGAP1 modulates its binding to Cdc42, revealing a new type of rho-GTPase regulator. J Biol Chem, 279, 48495-504.   DOI   ScienceOn
22 Hart MJ, Callow MG, Souza B, Polakis P (1996). IQGAP1, a calmodulin-binding protein with a rasGAP-related domain, is a potential effector for cdc42Hs. EMBO J, 15, 2997-3005.
23 Jadeski L, Mataraza JM, Jeong HW, Li Z, Sacks DB (2008). IQGAP1 stimulates proliferation and enhances tumorigenesis of human breast epithelial cells. J Biol Chem, 283, 1008-17.   DOI   ScienceOn
24 Jin SH, Akiyama Y, Fukamachi H, et al (2008). IQGAP2 inactivation through aberrant promoter methylation and promotion of invasion in gastric cancer cells. Int J Cancer, 122, 1040-6.
25 Berk V, Kaplan MA, Tonyali O, et al (2013). Efficiency and side effects of sorafenib therapy for advanced hepatocellular carcinoma: a retrospective study by the Anatolian society of medical oncology. Asian Pac J Cancer Prev, 14, 7367-9.   과학기술학회마을   DOI   ScienceOn
26 Brill S, Li S, Lyman CW, et al (1996). The Ras GTPase-activatingprotein-related human protein IQGAP2 harbors a potential actin binding domain and interacts with calmodulin and Rho family GTPases. Mol Cell Biol, 16, 4869-78.   DOI
27 Bernards A (2003). GAPs galore! A survey of putative Ras superfamily GTPase activating proteins in man and Drosophila. Biochim Biophys Acta, 1603, 47-82.
28 Breuhahn K, Longerich T, Schirmacher P (2006). Dysregulation of growth factor signaling in human hepatocellular carcinoma. Oncogene, 25, 3787-800.   DOI   ScienceOn
29 Briggs MW, Sacks DB (2003). IQGAP proteins are integral components of cytoskeletal regulation. Embo Rep, 4, 571-4.   DOI   ScienceOn
30 Brown MD, Sacks DB (2006). IQGAP1 in cellular signaling: bridging the GAP. Trends Cell Biol, 16, 242-9.   DOI   ScienceOn
31 Bruix J, Sherman M (2011). Management of hepatocellular carcinoma: an update. Hepatology, 53, 1020-2.   DOI   ScienceOn
32 Chen F, Zhu HH, Zhou LF, et al (2010). IQGAP1 is overexpressed in hepatocellular carcinoma and promotes cell proliferation by Akt activation. Exp Mol Med, 42, 477-83.   DOI   ScienceOn
33 Nabeshima K, Shimao Y, Inoue T, Koono M (2002). Immunohistochemical analysis of IQGAP1 expression in human colorectal carcinomas: its overexpression in carcinomas and association with invasion fronts. Cancer Lett, 176, 101-9.   DOI   ScienceOn
34 Eom DW, Kang GH, Han SH, et al (2011). Gastric micropapillary carcinoma: A distinct subtype with a significantly worse prognosis in TNM stages I and II. Am J Surg Pathol, 35, 84-91   DOI   ScienceOn
35 Casteel DE, Turner S, Schwappacher R, et al (2012). Rho isoformspecific interaction with IQGAP1 promotes breast cancer cell proliferation and migration. J Biol Chem, 287, 38367-78.   DOI
36 Xie Y, Yan J, Cutz JC, et al (2012). IQGAP2, A candidate tumour suppressor of prostate tumorigenesis. Biochim Biophys Acta, 1822, 875-84.   DOI   ScienceOn